Philips and Elekta Deepen Strategic Partnership in Precise and Individualized Oncology Care

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), and Elekta (EKTA-B.ST) signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions.

The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy. Through deeper cross-portfolio collaboration, Philips and Elekta will utilize their complementary capabilities to further improve patient care.

Benefiting patients throughout the care pathway

Oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.

This integrated approach has the potential to provide:

  • Quicker, more accurate visualization of the tumor
  • Easier decision of optimal treatment strategy
  • Earlier assessment of therapy response
  • More effective and efficient therapy delivery

The strengthened strategic partnership intends to further deliver a superior experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and more precise therapy for patients, and lowered costs of care for healthcare providers.

"To capitalize on the opportunities presented by increasingly precise diagnosis and the fast-expanding range of therapies available for cancer patients, it's essential to provide integrated systems and solutions that provide the right insights at the right time throughout each patient's care journey," said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. "By deepening our already-successful collaboration with Elekta, we will accelerate towards our goal of providing clear care pathways and predictable outcomes for every cancer patient. Today's announcement is an important next step in the implementation of our strategy in precision diagnosis."

"I expect this extended partnership to unlock opportunities that will provide better outcomes for people with cancer," said Gustaf Salford, Elekta's President and CEO. "Together, we'll combine advanced informatics and image-guided radiation therapy solutions to deliver greater precision in oncology. This means easier selection by clinicians of the optimal treatment strategy and more efficient and effective therapy delivery."

In this preferred, although non-exclusive, partnership, Elekta and Philips will leverage their capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties' systems and software in order to drive precision in oncology.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

About Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange.

Most Popular Now

Artificial Intelligence in Healthcare Re…

This study presents an overview of the development, adoption and use of Artificial Intelligence (AI) technologies and applications in the healthcare sector across all Member States. The main aim of...

New App Helps Parents Identify Treatable…

A ground-breaking new, mobile phone app, 'GrowthMonitor' places the accurate measurement of children's height in the hands of parents and carers. Preliminary data to be presented at the Society for...

Dedalus Acquires Swiftqueue to Support P…

Dedalus Group ("Dedalus"), a leading international healthcare software solutions provider, has announced to have completed the acquisition of 100% of Swiftqueue Technologies Ltd a fast-growing cloud-native appointment and scheduling solution...

Bittium Exhibits its High-Tech Medical T…

Bittium exhibits its innovative products and solutions for cardiology and neurophysiology as well as R&D services for the development of medical and healthcare technology at the MEDICA 2021 event. It...

Development of AI Technology for Produci…

Transcranial focused ultrasound can be used to treat degenerative movement disorders, intractable pain, and mental disorders by delivering ultrasound energy to a specific area of the brain without opening the...

FDA Authorizes Marketing of Virtual Real…

The U.S. Food and Drug Administration today authorized marketing of EaseVRx, a prescription-use immersive virtual reality (VR) system that uses cognitive behavioral therapy and other behavioral methods to help with...

Tulane University Study Uses AI to Detec…

A Tulane University researcher found that artificial intelligence (AI) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study...

Siemens Healthineers and UCSF Create Fir…

Siemens Healthineers and UC San Francisco have formed a research and innovation-driven collaboration to make radiological imaging greener, while improving access to and quality of radiological imaging in Northern California...

Open Call DIGITAL-2021-DEPLOY-01-HEALTH:…

The consolidation of a European framework and ecosystem of digital health solutions and services, covering technological and organisational innovation and addressing the needs of the involved stakeholders, including those of...

MEDICA 2021 + COMPAMED 2021: Holding the…

15 - 18 November 2021, Düsseldorf, Germany. This week, all of the big decision makers and professional experts from the international healthcare industry will finally be making their way to Düsseldorf...

MEDICA 2021 and COMPAMED 2021 have Far E…

15 - 18 November 2021, Düsseldorf, Germany. After their four-day run as an in-person event, MEDICA and COMPAMED have achieved extremely successful results in Düsseldorf. From 15 to 18 November 2021...

Philips Integrates MedChat's AI Capabili…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced a collaboration with USA-based MedChat to integrate MedChat's live chat and AI-driven chatbot services into Philips Patient...